These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1120 related items for PubMed ID: 18754026

  • 1. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
    Kilpivaara O, Levine RL.
    Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
    [Abstract] [Full Text] [Related]

  • 2. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

  • 3. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Oct; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 4. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY, Im K, Park SN, Kwon J, Kim JA, Lee DS.
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [Abstract] [Full Text] [Related]

  • 5. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
    Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA.
    BMC Cancer; 2019 Jun 17; 19(1):590. PubMed ID: 31208359
    [Abstract] [Full Text] [Related]

  • 6. JAK2 and MPL mutations in myeloproliferative neoplasms.
    Koppikar P, Levine RL.
    Acta Haematol; 2008 Jun 17; 119(4):218-25. PubMed ID: 18566540
    [Abstract] [Full Text] [Related]

  • 7. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
    Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.
    Leukemia; 2008 Jul 17; 22(7):1299-307. PubMed ID: 18496562
    [Abstract] [Full Text] [Related]

  • 8. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K, Shimoda K.
    Rinsho Byori; 2009 Apr 17; 57(4):357-64. PubMed ID: 19489438
    [Abstract] [Full Text] [Related]

  • 9. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
    Poluben LO, Neumerzhytska LV, Klymenko SV, Fraenkel P, Balk C, Shumeiko OO.
    Probl Radiac Med Radiobiol; 2020 Dec 17; 25():362-373. PubMed ID: 33361847
    [Abstract] [Full Text] [Related]

  • 10. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
    Tefferi A.
    Am J Hematol; 2016 Jan 17; 91(1):50-8. PubMed ID: 26492355
    [Abstract] [Full Text] [Related]

  • 11. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A.
    Am J Hematol; 2008 Jun 17; 83(6):491-7. PubMed ID: 18429051
    [Abstract] [Full Text] [Related]

  • 12. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
    Liu L, Xiao ZJ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb 17; 19(1):239-43. PubMed ID: 21362261
    [Abstract] [Full Text] [Related]

  • 13. Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.
    Plo I, Vainchenker W.
    Clin Lymphoma Myeloma; 2009 Feb 17; 9 Suppl 3():S329-39. PubMed ID: 19778861
    [Abstract] [Full Text] [Related]

  • 14. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
    Wang J, Ishii T, Zhang W, Sozer S, Dai Y, Mascarenhas J, Najfeld V, Zhao ZJ, Hoffman R, Wisch N, Xu M.
    Leukemia; 2009 Sep 17; 23(9):1577-86. PubMed ID: 19387466
    [Abstract] [Full Text] [Related]

  • 15. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
    Vainchenker W, Kralovics R.
    Blood; 2017 Feb 09; 129(6):667-679. PubMed ID: 28028029
    [Abstract] [Full Text] [Related]

  • 16. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS.
    Asian Pac J Cancer Prev; 2016 Feb 09; 17(3):923-6. PubMed ID: 27039813
    [Abstract] [Full Text] [Related]

  • 17. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H, Spivak JL.
    Clin Adv Hematol Oncol; 2009 May 09; 7(5):334-42. PubMed ID: 19521323
    [Abstract] [Full Text] [Related]

  • 18. Molecular genetic evaluation of myeloproliferative neoplasms.
    Azzato EM, Bagg A.
    Int J Lab Hematol; 2015 May 09; 37 Suppl 1():61-71. PubMed ID: 25976962
    [Abstract] [Full Text] [Related]

  • 19. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.
    J Clin Oncol; 2007 Mar 20; 25(9):1048-53. PubMed ID: 17369568
    [Abstract] [Full Text] [Related]

  • 20. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R.
    N Engl J Med; 2013 Dec 19; 369(25):2379-90. PubMed ID: 24325356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.